NMDA receptor, PKC and ERK prevent fos expression induced by the activation of group I metabotropic glutamate receptors in the spinal trigeminal subnucleus oralis

Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation

Parkinson's disease (PD) is a common neurodegenerative disorder of middle-aged and elderly people, clinically characterized by resting tremor, myotonia, reduced movement, and impaired postural balance. Clinically, patients with PD are often administered levodopa (L-DOPA) to improve their symptoms. However, after years of L-DOPA treatment, most patients experience complications of varying severity, including the "on-off phenomenon", decreased efficacy, and levodopa-induced dyskinesia (LID). The development of LID can seriously affect the quality of life of patients, but its pathogenesis is unclear and effective treatments are lacking. Glutamic acid (Glu)-mediated changes in synaptic plasticity play a major role in LID. The N-methyl-D-aspartic acid receptor (NMDAR), an ionotropic glutamate receptor, is closely associated with synaptic plasticity, and neuroinflammation can modulate NMDAR activation or expression; in addition, neuroinflammation may be involved in the development of LID. However, it is not clear whether NMDA receptors are co-regulated with neuroinflammation during LID formation. Here we review how neuroinflammation mediates the development of LID through the regulation of NMDA receptors, and assess whether common anti-inflammatory drugs and NMDA receptor antagonists may be able to mitigate the development of LID through the regulation of central neuroinflammation, thereby providing a new theoretical basis for finding new therapeutic targets for LID.

Differential roles of signal transduction mechanisms in long-term potentiation of excitatory synaptic transmission induced by activation of group I mGluRs in the spinal trigeminal subnucleus oralis

Group I metabotropic glutamate receptors (mGluR1 and 5) have been implicated in long-term potentiation (LTP), a persistent increase of synaptic efficiency, in the central nervous system including the spinal trigeminal nucleus (Vsp). In the ascending pathway from the caudalis (Vc) to the oralis (Vo) subnuclus in Vsp, it has been shown that the activation of group I mGluRs (mGluR1 and 5) with their agonist (S)-3,5-dihydroxyphenylglycine (DHPG) produces a delayed type of LTP of excitatory synaptic transmission and this LTP was mediated by mGluR1. Further, this study attempts to pharmacologically characterize essential signaling components for the expression of DHPG-induced LTP. As a result, it is found that the group I mGluRs essentially use G protein-mediated activation of the phospholipase C (PLC) pathway to express the LTP. However, recruited signaling molecules following the activation of PLC are differentially involved in the expression of LTP: i.e. IP3 receptor, intracellular Ca(2+) rise, CaMKII and ERK function as positive regulators, whereas PKC as a negative regulator. Furthermore, both L-type voltage-dependent Ca(2+) channel and canonical transient receptor potential channel positively contribute to the expression of LTP. Taken together, these results suggest that signaling molecules recruited by the activation of group I mGluRs collaboratively or oppositely control the optimal expression of synaptic plasticity at excitatory synapses in the Vo.